UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000003672
Receipt No. R000004328
Scientific Title Phase II study of adjuvant chemotherapy of OPTIMOX therapy (intermittent FOLFOX regimen) for Stage III colon cancer (including Rectosigmoid cancer).
Date of disclosure of the study information 2010/06/01
Last modified on 2010/05/28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase II study of adjuvant chemotherapy of OPTIMOX therapy (intermittent FOLFOX regimen) for Stage III colon cancer (including Rectosigmoid cancer).
Acronym Triple 4 study
Scientific Title Phase II study of adjuvant chemotherapy of OPTIMOX therapy (intermittent FOLFOX regimen) for Stage III colon cancer (including Rectosigmoid cancer).
Scientific Title:Acronym Triple 4 study
Region
Japan

Condition
Condition Colon cancer (including Rectosigmoid cancer)
Classification by specialty
Gastrointestinal surgery Hepato-biliary-pancreatic surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 The primary end piont of this study is to assess the efficacy and safety of OPTIMOX therapy (intermittent FOLFOX regimen) as adjuvant chemotherapy for Stage III colon cancer including Rectosigmoid cancer.
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Phase II

Assessment
Primary outcomes The incidence of oxaliplatin induced neuropathy.
Key secondary outcomes The incidence of all adverse events (Excluding neuropathy).
Disease free survival (DFS)
Overall survival (OS)

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Adjuvant chemotherapy

Oxaliplatin 85mg/m2/bi-week(day1)
l-LV 200 mg/m2/bi-week(day1)
5-FU/bolus 400mg/m2/bi-week bolus(day1)
5-FU/infusional 2400mg/m2/bi-week(day1-3)
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >=
Gender Male and Female
Key inclusion criteria 1.Histologically confirmed Colorectal adenocarcinoma and histological Stage III Colon cancer (including Rectosigmoid cancer).
2.Curative resection with D2 or more extensive lymph node dissection.
3.Resection of histological curability A was performed.
4.Age: 20-80 years old.
5.Performance status (ECOG):0-2
6.No prior chemotherapy and radiotherapy and immunotherapy.
7.Adequate organ function.
* WBC:3,000/mm3-12,000/mm3
* Neutrophil count <=1500/mm3.
* Platelet count<=;100,000/mm3.
Liver function tests
* AST (GOT) and ALT (GPT)>=;2.5*ULN.
* Total bilirubin>=;2.5*ULN.
Renal function test
* Serum creatinine>=;1.25*ULN.
8.Chemotherapy will be started within 8 weeks from operation.
9.Written informed consent.
Key exclusion criteria 1.Pregnant or nursing
2.Administering antithrobotic drug within 14 days
3.Medical history of allergy or hypersensitivity reactions.
4.Peripheral neuropathy (CTC AE v3.0 <= Grade1)
5.Active infection
6.Serious complications (renal failure or hepatic failure or heart failure)
7.Interstitial pnumonitis, pulmonary fibrosis or high-grade pulmonary emphysema.
8.Treated heart disease within 12 months
9.History of mental disturbances or cerebrovascular attack.
10.Watery diarrhea.
11.History of other colorectal cancer (including; sarcoma, carcinoid, lymphoma etc).
12.History of cancer (disease free interval was less than 10 years)
13.Double cancer.
14.Other conditions not suitable for this study
Target sample size 85

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Iwao Sasaki
Organization Tohoku University Graduate School of Medicine
Division name Division of Biological-regulation and Oncology
Zip code
Address 1-1, Seiryo-machi, Aoba-ku, Sendai, 980-8574, JAPAN
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name Toshinori Ando, Koh Miura
Organization Tohoku University Graduate School of Medicine
Division name Division of Biological-regulation and Oncology
Zip code
Address 1-1, Seiryo-machi, Aoba-ku, Sendai, 980-8574, JAPAN
TEL 022-217-7205
Homepage URL
Email

Sponsor
Institute Tohoku University Graduate School of Medicine
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2010 Year 06 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2010 Year 01 Month 26 Day
Date of IRB
Anticipated trial start date
2010 Year 02 Month 01 Day
Last follow-up date
2015 Year 12 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2010 Year 05 Month 28 Day
Last modified on
2010 Year 05 Month 28 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004328

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.